NCT04802174 2026-03-17
Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine Cancers
National Institutes of Health Clinical Center (CC)
Phase 1/2 Active not recruiting
Clinical Trials
5 trialsNCT05091567 2026-03-10
IMforte
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04607954 2026-01-06
Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer
Mayo Clinic
Phase 2 Active not recruiting
NCT05740566 2026-01-05
DeLLphi-304
Amgen
Phase 3 Active not recruiting
NCT05099666 2025-12-09
Lurbinectedin + Doxorubicin In Leiomyosarcoma
Massachusetts General Hospital
Phase 1/2 Active not recruiting